Available IPD datapackage for study 'An Open-label, Multicenter, Phase 2 Study of Oral IXAZOMIB (MLN9708) in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma'

The primary purpose of this study is to evaluate the anti-tumor activity of oral Ixazomib as
measured by overall response rate (ORR) in adult participants with relapsed and/or refractory
follicular lymphoma (FL).

本研究的主要目的为，以总缓解率（ORR）为衡量指标，评估口服伊沙佐米（Ixazomib）在复发性和/或难治性滤泡性淋巴瘤（FL）成年受试者中的抗肿瘤活性。